TrialThe New England journal of medicine2017
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Mark H Wilcox et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
425 papers cite itlatest 60 shown
this paperpooled ittrialcites it